专利检索 cpc:"C07D215/12" 第 1 页

1.

发明公开
Covalent Inhibitors As Antiviral Agents 审中-公开

公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

申请人： Enanta Pharmaceuticals, Inc.

发明人： Xuri GAO , Bin WANG , Hui CAO , Jiajun ZHANG , Yuk Ming SIU , Jiang LONG , Wei LI , Matthew C. RHODES , Xuechao XING , Jianming YU , Scott MITCHELL , Yat Sun OR

IPC分类号： C07C233/56 , A61K31/166 , A61K31/277 , A61K31/337 , A61K31/365 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/403 , A61K31/415 , A61K31/4152 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4439 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/506 , A61K31/535 , A61K31/662 , A61P31/14 , C07C243/30 , C07C255/46 , C07C255/66 , C07D205/04 , C07D207/16 , C07D209/52 , C07D209/56 , C07D213/40 , C07D215/12 , C07D231/08 , C07D231/12 , C07D231/56 , C07D239/26 , C07D241/12 , C07D249/06 , C07D263/32 , C07D263/34 , C07D265/02 , C07D277/28 , C07D295/185 , C07D305/08 , C07D307/58 , C07D333/20 , C07D333/24 , C07D401/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14 , C07F9/40

CPC分类号： C07C233/56 , A61K31/166 , A61K31/277 , A61K31/337 , A61K31/365 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/403 , A61K31/415 , A61K31/4152 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4439 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/506 , A61K31/535 , A61K31/662 , A61P31/14 , C07C243/30 , C07C255/46 , C07C255/66 , C07D205/04 , C07D207/16 , C07D209/52 , C07D209/56 , C07D213/40 , C07D215/12 , C07D231/08 , C07D231/12 , C07D231/56 , C07D239/26 , C07D241/12 , C07D249/06 , C07D263/32 , C07D263/34 , C07D265/02 , C07D277/28 , C07D295/185 , C07D305/08 , C07D307/58 , C07D333/20 , C07D333/24 , C07D401/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14 , C07F9/4015

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

2.

发明公开
A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF 审中-公开

公开(公告)号：US20240208922A1

公开(公告)日：2024-06-27

申请号：US18287136

申请日：2022-04-12

申请人： Studiengesellschaft Kohle gGmbH

发明人： Tobias RITTER , Andreas HAERING

IPC分类号： C07D339/08 , C07C17/32 , C07C41/22 , C07C67/30 , C07C67/475 , C07C231/12 , C07C269/06 , C07C303/40 , C07C319/14 , C07D209/48 , C07D215/12 , C07D215/36 , C07D277/74 , C07D333/54 , C07D453/04 , C07D473/12 , C07D493/14 , C07H15/02 , C07J1/00 , C07J9/00

CPC分类号： C07D339/08 , C07C17/32 , C07C41/22 , C07C67/30 , C07C67/475 , C07C231/12 , C07C269/06 , C07C303/40 , C07C319/14 , C07D209/48 , C07D215/12 , C07D215/36 , C07D277/74 , C07D333/54 , C07D453/04 , C07D473/12 , C07D493/14 , C07H15/02 , C07J1/0011 , C07J9/005

摘要： The present inventions refers a novel trifluoromethyl thianthrenium compound referred to as TT-CF3+X−, a process for preparing the same and the use thereof for trifluoromethylating organic compounds.

3.

发明授权
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse 有权

公开(公告)号：US11999676B2

公开(公告)日：2024-06-04

申请号：US16848462

申请日：2020-04-14

申请人： University of Kentucky Research Foundation

发明人： Linda P. Dwoskin , David Watt , Jon Thorson , Mark Leggas , Kip Guy , Jared Hammill , Stefan Kwiatkowski , Derong Ding , Guangrong Zheng , Peter Anthony Crooks , Na-Ra Lee

IPC分类号： C07C211/53 , C07C233/43 , C07D209/14 , C07D213/38 , C07D215/12

CPC分类号： C07C211/53 , C07C233/43 , C07D209/14 , C07D213/38 , C07D215/12

摘要： The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

4.

发明授权
Alpha-cinnamide compounds and compositions as HDAC8 inhibitors 有权

公开(公告)号：US11919839B2

公开(公告)日：2024-03-05

申请号：US17238529

申请日：2021-04-23

申请人： Valo Health, Inc.

发明人： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng

IPC分类号： C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10

CPC分类号： C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10 , Y02A50/30

摘要： The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

5.

发明授权
Nitrogen-containing compound, electronic element and electronic device 有权

公开(公告)号：US11827615B2

公开(公告)日：2023-11-28

申请号：US17528554

申请日：2021-11-17

申请人： Shaanxi Lighte Optoelectronics Materials Co., Ltd.

发明人： Qiqi Nie , Jiamei Cao , Tiantian Ma

IPC分类号： C07D333/76 , C07C211/54 , C07D209/82 , C07D209/86 , C07D209/88 , C07D213/36 , C07D215/12 , C07D265/38 , C07D307/91 , C07D311/80 , C07D319/24 , C07D339/08 , C07D403/12 , C07D405/12 , C07D409/12 , C07D471/04 , C07F7/08 , H10K85/60 , H10K50/15

CPC分类号： C07D333/76 , C07C211/54 , C07D209/82 , C07D209/86 , C07D209/88 , C07D213/36 , C07D215/12 , C07D265/38 , C07D307/91 , C07D311/80 , C07D319/24 , C07D339/08 , C07D403/12 , C07D405/12 , C07D409/12 , C07D471/04 , C07F7/0816 , H10K85/631 , H10K85/633 , H10K85/636 , H10K85/654 , H10K85/6572 , H10K85/6574 , H10K85/6576 , H10K50/156

摘要： The present disclosure provides a nitrogen-containing compound, an electronic element and an electronic device, which belongs to the technical field of organic materials. The nitrogen-containing compound has a structure of Chemical Formula 1, wherein R1 and R2 are each independently selected from hydrogen or a group represented by Chemical Formula 1-1, and one and only one of R1 and R2 has the group of Chemical Formula 1-1; when R1 or R2 is selected from hydrogen, said R1 and R2 may be replaced by R4. The nitrogen-containing compound can improve the performance of electronic elements.

6.

发明公开
ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME 审中-公开

公开(公告)号：US20230337527A1

公开(公告)日：2023-10-19

申请号：US17924785

申请日：2021-04-19

申请人： LAPTO CO., LTD.

发明人： Gyu-ri KIM , Gyung-woo KIM , Moon-ki SEOK , Kyou-sic KIM , Kap-jong HAN , Eu-gene OH

IPC分类号： H10K85/60 , C07C25/22 , C07C22/08 , C07D213/26 , C07D215/12 , C07D307/91 , C07D491/048 , C07D333/76 , C07D401/04 , C07D405/04 , H10K50/858

CPC分类号： H10K85/626 , C07C22/08 , C07C25/22 , C07D213/26 , C07D215/12 , C07D307/91 , C07D333/76 , C07D401/04 , C07D405/04 , C07D491/048 , H10K50/858 , H10K85/653 , H10K85/654 , H10K85/655

摘要： Disclosed is an organic compound contributing to improving the substantial light efficiency and field of view of an organic electroluminescent device. The organic electroluminescent device contains a first electrode; a second electrode; one or more organic material layers disposed between the first electrode and the second electrode; and a capping layer, wherein the organic material layers or capping layer contains an organic compound of chemical formula 1:

7.

发明授权
Methods of reducing color in alkanolamine compositions and compositions produced thereby 有权

公开(公告)号：US11746080B2

公开(公告)日：2023-09-05

申请号：US16809910

申请日：2020-03-05

申请人： SABIC Global Technologies B.V.

发明人： Feng Xu , Flaiyh Al-Anazi

IPC分类号： C07C213/10 , C07F5/02 , C07D215/08 , C07D215/10 , C07D215/12

CPC分类号： C07C213/10 , C07F5/022 , C07F5/027 , C07D215/08 , C07D215/10 , C07D215/12 , C07C213/10 , C07C215/08 , C07C213/10 , C07C215/10 , C07C213/10 , C07C215/12

摘要： A method of reducing color in an alkanolamine is described. The method includes contacting the alkanolamine with a color-reducing amount of a borane complex effective to provide a color-reduced alkanolamine composition having a Platinum-Cobalt Color Value, according to Test Method ASTM D1209, of less than 50.

8.

发明公开
FUNCTIONALIZED FLUOROALKYL SILANE, AND SYNTHETIC METHOD THEREFOR AND APPLICATION THEREOF 审中-公开

公开(公告)号：US20230257402A1

公开(公告)日：2023-08-17

申请号：US18031243

申请日：2021-11-01

申请人： EAST CHINA NORMAL UNIVERSITY

发明人： Jian ZHOU , BoShuai MU , JinSheng YU

IPC分类号： C07F7/18 , C07F7/08 , C07F7/12 , C07D453/04 , C07C33/18 , C07D215/12

CPC分类号： C07F7/1804 , C07F7/081 , C07F7/12 , C07D453/04 , C07F7/0834 , C07C33/18 , C07D215/12

摘要： Disclosed in the present invention are a functionalized fluoroalkyl silane compound and a synthetic method therefor. The method comprises: dissolving a halosilane and a fluoroalkyl source in an organic solvent; and synthesizing functionalized fluoroalkyl silane under the effect of an alkali or a tertiary phosphine compound. The functionalized fluoroalkyl silane can not only be used for constructing a series of high added-value compounds such as fluoroalkyl substituted alcohols, ketones and amines that can be constructed by conventional TMSRf, but also can transfer, by means of appropriate conversion, a functional group on a silicon protecting group to the obtained addition product in an addition reaction, for synthesizing some fluorine-containing compounds that cannot be synthesized by using a conventional TMSRf reagent, thereby greatly improving the synthesis efficiency and the atom economy of reactions. Also disclosed in the present invention are more excellent reaction efficiency and enantioselectivity, compared with conventional TMSCF3, exhibited by trifluoromethyl chloromethylsilane in synthesis of a 2-trifluoromethylquinoline compound and in an asymmetric trifluoromethylation reaction with α,β-unsaturated ketones.